HOPA 2023: Integrating BCMA-Targeted Therapies Into R/R Multiple Myeloma Care: Opportunities for Pharmacists

Therapies targeting B-cell maturation antigen (BCMA) are transforming the approach to treatment in relapsed/refractory (R/R) multiple myeloma. Review the latest expert updates on the integration and use of BCMA-targeted therapies to optimize overall patient care in R/R multiple myeloma and strategies to monitor and mitigate adverse events with a live and on-demand webcast, a downloadable slideset from the webcast, and a focused commentary.

In coordination with HOPA's Annual Conference

Share

Program Content

Activities

BCMA MM Pharmacist
Integrating BCMA-Targeted Therapies Into R/R Multiple Myeloma Care: Opportunities for Pharmacists
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: May 03, 2023

Activities

BCMA-Targeted Therapies
Integrating BCMA-Targeted Therapies Into R/R Multiple Myeloma Care: Opportunities for Pharmacists
Video
Congratulations: You achieved a completion on 04/09/2022

Released: June 14, 2023

Expires: June 13, 2024

Activities

CRS in MM
Our Thoughts on Cytokine Release Syndrome With BCMA-Targeted Therapies for Relapsed/Refractory Multiple Myeloma
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: June 19, 2023

Faculty

cover img faculity

Donald C. Moore, PharmD, BCPS, BCOP, DPLA, FCCP

Clinical Oncology Pharmacy Manager
Atrium Health Levine Cancer Institute
Charlotte, North Carolina

cover img faculity

Victoria R. Nachar, PharmD, BCOP

Clinical Pharmacist Specialist, Hematology
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan

Provided by

ProCE Banner

Provided by ProCE, LLC.

Supporters

Supported by an educational grant from Bristol Myers Squibb.

Bristol Myers Squibb

Partners

Clinical Care Options, LLC

ProCE Banner

Hematology/Oncology Pharmacy Association (HOPA)

ProCE Banner

In partnership with Clinical Care Options, LLC and the Hematology/Oncology Pharmacy Association (HOPA).